Journal
NUCLEIC ACIDS RESEARCH
Volume 39, Issue 4, Pages 1266-1279Publisher
OXFORD UNIV PRESS
DOI: 10.1093/nar/gkq861
Keywords
-
Categories
Funding
- Cancer Research UK
- Association for International Cancer Research
- Cancer Research UK Association for International Cancer Research
- MRC [G0601123, G0900871] Funding Source: UKRI
- Academy of Medical Sciences (AMS) [AMS-SGCL4-McCracken] Funding Source: researchfish
- Medical Research Council [G0900871, G0601123] Funding Source: researchfish
Ask authors/readers for more resources
The androgen receptor (AR) is a member of the nuclear hormone receptor family of transcription factors that plays a critical role in regulating expression of genes involved in prostate development and transformation. Upon hormone binding, the AR associates with numerous co-regulator proteins that regulate the activation status of target genes via flux to the post-translational modification status of histones and the receptor. Here we show that the AR interacts with and is directly methylated by the histone methyltransferase enzyme SET9. Methylation of the AR on lysine 632 is necessary for enhancing transcriptional activity of the receptor by facilitating both inter-domain communication between the N- and C-termini and recruitment to androgen-target genes. We also show that SET9 is pro-proliferative and anti-apoptotic in prostate cancer cells and demonstrates up-regulated nuclear expression in prostate cancer tissue. In all, our date indicate a new mechanism of AR regulation that may be therapeutically exploitable for prostate cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available